Verdad Advisers’s Maze Therapeutics MAZE Stock Holding History
Bought
Maintained
Sold
Other funds holding MAZE
Verdad Advisers's MAZE Position: Q3 2026 in Review
Verdad Advisers increased its Maze Therapeutics (MAZE) stake by 1.7% in Q3 2026, buying an estimated $5.86K and bringing the position to 12,829 shares worth $349K. The position accounts for 0.37% of the portfolio, ranked #102.
Verdad Advisers first reported a position in MAZE in Q2 2026 and has held it in 2 quarters since. The position peaked at $377K in Q2 2026. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.
- Verdad Advisers held 12,829 shares of Maze Therapeutics worth $349K as of Q3 2026.
- Verdad Advisers bought 211 Maze Therapeutics shares in Q3 2026, an estimated $5.86K.
- Maze Therapeutics made up 0.37% of Verdad Advisers's portfolio in Q3 2026, its #102 holding.
- Verdad Advisers first reported a position in Maze Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Verdad Advisers's Maze Therapeutics position peaked at $377K in Q2 2026.
- 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.
Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.